-
AstraZeneca Expands China Presence with Over 30 Agreements at CIIE
•
At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc (AZ; NASDAQ: AZN) has signed over 30 agreements with Chinese provincial governments and other entities, marking a significant expansion in China. The agreements include substantial investments and collaborations aimed at enhancing local production, improving access…
-
Moderna Initiates Construction of First China-Based Pharmaceutical Plant in Shanghai
•
S-based mRNA specialist, Moderna (NASDAQ: MRNA), has commenced construction on its inaugural pharmaceutical facility in China, as reported by Xinhua. The new plant, situated in Shanghai’s Minhang District at the Xinzhuang Industry Park, is set to serve as Moderna’s China R&D and production headquarters. The project has attracted an investment…
-
Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China
•
Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration and license agreement with Shanghai-based Celest Therapeutics Co., Ltd. The partnership will see Celest manage a pilot clinical trial in mainland China for Senti’s SENTI-301A, an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing tumors. Senti will…
-
Eisai Partners with Shanghai Pharmaceuticals for Alzheimer’s Drug Leqembi in China
•
Eisai (TYO: 4523), a Japan-headquartered pharmaceutical company, has entered into a significant partnership with Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading China-based pharmaceutical distribution giant, to collaborate on the Alzheimer’s disease (AD) drug Leqembi (lecanemab). The deal is potentially valued at RMB 1.5 billion (USD 205 million) and…
-
Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China
•
Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a partnership with Shanghai Pharmaceuticals, a leading China-based pharmaceutical distribution giant (SPH; HKG: 2607; SHA: 601607), to co-construct a new life sciences incubator named Co.Lab. This collaboration is designed to foster cutting-edge innovation in cell and…
-
Abbisko Therapeutics Receives FDA Approval for Phase I Study of FGFR4 Inhibitor ABSK012
•
Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received clearance from the US Food and Drug Administration (FDA) to commence a Phase I clinical study of its next-generation FGFR4 mutant inhibitor, ABSK012, for the treatment of advanced solid tumors. Objectives of the Phase I…
-
Fosun Pharmaceutical and Insightec Collaborate on Non-Invasive Brain Treatment Technology
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based medical device company Insightec Ltd, a leader in magnetic resonance (MR)-guided Focused Ultrasound equipment. This partnership aims to apply Insightec’s advanced Focused Ultrasound brain therapy technology for the treatment of idiopathic tremors and Parkinson’s disease…
